Human Genome Project Deadline Moves Up Two Years, to 2003

GENOME SYMBOL: DNA strands form the basis of a graphic symbol of the genome project. They said it wasn't a race. When a private venture announced plans in May to produce a version of the human genome four years ahead of the international nonprofit Human Genome Project's deadline, scientists associated with the public project insisted that the private effort wasn't really a challenge to theirs. The private effort would present, at best, a "rough draft" with many holes--if it worked at all, they

Written byPaul Smaglik
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share


GENOME SYMBOL: DNA strands form the basis of a graphic symbol of the genome project.
They said it wasn't a race. When a private venture announced plans in May to produce a version of the human genome four years ahead of the international nonprofit Human Genome Project's deadline, scientists associated with the public project insisted that the private effort wasn't really a challenge to theirs. The private effort would present, at best, a "rough draft" with many holes--if it worked at all, they argued [P. Smaglik, The Scientist, 12[12]:1, June 8, 1998].

Now, however, leaders of the public project have responded by announcing that the international effort will produce its own "working draft" of the human genome sequence by the end of 2001--roughly the same deadline for the project sponsored by the company now known as Celera Inc., a Rockville, Md.-based business formed by J. Craig Venter, former director of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies